WO2009063990A1 - ベンズアゼピノン化合物 - Google Patents

ベンズアゼピノン化合物 Download PDF

Info

Publication number
WO2009063990A1
WO2009063990A1 PCT/JP2008/070804 JP2008070804W WO2009063990A1 WO 2009063990 A1 WO2009063990 A1 WO 2009063990A1 JP 2008070804 W JP2008070804 W JP 2008070804W WO 2009063990 A1 WO2009063990 A1 WO 2009063990A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
benzazepinone compound
alkyl group
group
benzazepinone
Prior art date
Application number
PCT/JP2008/070804
Other languages
English (en)
French (fr)
Inventor
Naoto Suzuki
Yasunori Tsuzaki
Kimihiko Yoshimura
Masahiko Hagihara
Yukinori Wada
Masao Maruyama
Nobuyoshi Fujii
Yasuhiro Aga
Original Assignee
Ube Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries, Ltd. filed Critical Ube Industries, Ltd.
Priority to US12/743,223 priority Critical patent/US8377922B2/en
Priority to CN2008801162434A priority patent/CN101861319B/zh
Priority to AU2008321770A priority patent/AU2008321770B2/en
Priority to CA2705916A priority patent/CA2705916C/en
Priority to JP2009541192A priority patent/JP5359879B2/ja
Priority to EP08850399.0A priority patent/EP2221308B1/en
Priority to ES08850399T priority patent/ES2428896T3/es
Publication of WO2009063990A1 publication Critical patent/WO2009063990A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　本発明は、下記式（Ｉ）： 【化１】 式中、Ｒ１は、Ｃ１－Ｃ６アルキル基又はハロゲノＣ１－Ｃ６アルキル基を示し、Ｒ２は、保護されていてもよいカルボキシ基を示し、Ｙは、一般式（ＩＩ）： 【化２】 式中、Ｚは、ＣＨ又は窒素原子を示す、 を示す、 で表されるベンズアゼピノン化合物又はその薬理上許容される塩に関する。
PCT/JP2008/070804 2007-11-16 2008-11-14 ベンズアゼピノン化合物 WO2009063990A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/743,223 US8377922B2 (en) 2007-11-16 2008-11-14 Benzazepinone compound
CN2008801162434A CN101861319B (zh) 2007-11-16 2008-11-14 苯并氮杂*酮化合物
AU2008321770A AU2008321770B2 (en) 2007-11-16 2008-11-14 Benzazepinone compound
CA2705916A CA2705916C (en) 2007-11-16 2008-11-14 Benzazepinone compound
JP2009541192A JP5359879B2 (ja) 2007-11-16 2008-11-14 ベンズアゼピノン化合物
EP08850399.0A EP2221308B1 (en) 2007-11-16 2008-11-14 Benzazepinone compound
ES08850399T ES2428896T3 (es) 2007-11-16 2008-11-14 Compuesto de benzacepinona

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007297532 2007-11-16
JP2007-297532 2007-11-16

Publications (1)

Publication Number Publication Date
WO2009063990A1 true WO2009063990A1 (ja) 2009-05-22

Family

ID=40638836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070804 WO2009063990A1 (ja) 2007-11-16 2008-11-14 ベンズアゼピノン化合物

Country Status (9)

Country Link
US (1) US8377922B2 (ja)
EP (1) EP2221308B1 (ja)
JP (1) JP5359879B2 (ja)
KR (1) KR101588469B1 (ja)
CN (1) CN101861319B (ja)
AU (1) AU2008321770B2 (ja)
CA (1) CA2705916C (ja)
ES (1) ES2428896T3 (ja)
WO (1) WO2009063990A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113958A1 (ja) * 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
US8377922B2 (en) 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
JP6309536B2 (ja) * 2012-12-11 2018-04-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二量体化合物
RU2769702C2 (ru) * 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997025325A1 (en) 1996-01-12 1997-07-17 Takeda Chemical Industries, Ltd. Carbapenem compounds, their production and use
WO1998014192A1 (en) 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
WO1999006049A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
WO1999015170A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999015178A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO2002090325A2 (en) 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
JP2004502635A (ja) * 1999-09-27 2004-01-29 アムジエン・インコーポレーテツド 縮合シクロヘプタンおよび縮合アザシクロヘプタン化合物ならびにそれらの使用方法
WO2004089890A2 (en) 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO2000038730A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
WO2000046215A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
MXPA04000839A (es) 2001-08-01 2004-05-14 Merck Patent Gesellscahft Mit Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996000730A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997025325A1 (en) 1996-01-12 1997-07-17 Takeda Chemical Industries, Ltd. Carbapenem compounds, their production and use
WO1998014192A1 (en) 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
JP2001501936A (ja) * 1996-10-02 2001-02-13 スミスクライン・ビーチャム・コーポレイション ビトロネクチンレセプター拮抗物質
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
WO1999006049A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
WO1999015170A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999015178A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
JP2004502635A (ja) * 1999-09-27 2004-01-29 アムジエン・インコーポレーテツド 縮合シクロヘプタンおよび縮合アザシクロヘプタン化合物ならびにそれらの使用方法
WO2002090325A2 (en) 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
WO2004089890A2 (en) 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 96, 1999, pages 319
GOODMAN ET AL., J. MED. CHEM., vol. 45, 2002, pages 1045
J. MED. CHEM., vol. 45, 2002, pages 1045
JUKIANO ET AL., EXP. CELL RES., vol. 225, no. 1, 1996, pages 132
MOL. CELL BIOL., vol. 27, 2007, pages 4444
See also references of EP2221308A4

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377922B2 (en) 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound
WO2010113958A1 (ja) * 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
CN102427816A (zh) * 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物

Also Published As

Publication number Publication date
KR20100106391A (ko) 2010-10-01
CN101861319B (zh) 2013-12-11
US20100249396A1 (en) 2010-09-30
KR101588469B1 (ko) 2016-01-25
CN101861319A (zh) 2010-10-13
EP2221308A4 (en) 2011-06-22
ES2428896T3 (es) 2013-11-12
EP2221308A1 (en) 2010-08-25
CA2705916A1 (en) 2009-05-22
CA2705916C (en) 2016-01-05
US8377922B2 (en) 2013-02-19
EP2221308B1 (en) 2013-07-10
JP5359879B2 (ja) 2013-12-04
AU2008321770B2 (en) 2012-09-06
AU2008321770A1 (en) 2009-05-22
JPWO2009063990A1 (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2009063990A1 (ja) ベンズアゼピノン化合物
WO2008096829A1 (ja) ３環系化合物
WO2008096820A1 (ja) ビフェニル誘導体
MX2010008745A (es) Inhibidor de fibrosis.
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2009028543A1 (ja) 置換ピラゾール誘導体
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2008108386A1 (ja) 医薬組成物
WO2009057079A3 (en) Novel pyrimidine derivatives
MY148703A (en) Polycyclic cinnamide derivatives
TW200744588A (en) Pharmaceutical composition for external use
WO2005099688A3 (en) Cyclic compounds
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
TW200740758A (en) Benzoquinazoline derivatives
GEP20115251B (en) Smac peptidomimetics useful as iap inhibitors
EP1889842A4 (en) HETEROCYCLIC CONNECTION
MY150507A (en) Polycyclic compound
WO2007103839A3 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
AU2006251620A8 (en) Imidazolone phenylalanine derivatives as VLA-4 antagonists
WO2008126890A1 (ja) ヒドラジド化合物およびそれを含有する有害節足動物防除剤
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators
WO2007133352A3 (en) Macrocyclic kinase inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880116243.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08850399

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009541192

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12743223

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2705916

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3825/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008850399

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107013195

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008321770

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008321770

Country of ref document: AU

Date of ref document: 20081114

Kind code of ref document: A